All News
Plenary abstract #OP0010: Fecal microbiota transplant (FMT) found to be inferior to sham in treating active peripheral PsA. No SAEs in patients treated with FMT. @RheumNow #EULAR2021 https://t.co/a5HgrJ4y1C https://t.co/Jk9FQZdn4B
Dr. Rachel Tate uptoTate ( View Tweet)
Does Fecal transplant work to treat PsA?
per FLORA trial: No benefits from fecal microbiotia transplantation vs sham in PsA w/ active dz despite MTX (limited by small size, high placebo response) - Dr. M Kragsnaes Abstr#OP0010 #EULAR2021 @rheumnow https://t.co/I7PsWgK9uA https://t.co/OKC4QcH8Nq
k dao KDAO2011 ( View Tweet)
Wow!
Video vaccine education message directly sent to patient cell phones by SMS is low cost, simple and effective to educate rheum patients about #COVIDvaccine. 76.6% of pts were more likely to take the vaccine.
Abst#OP0009-PARE #EULAR2021 @rheumnow Dr. L Rajagopala https://t.co/OLBOSrmHVR
k dao KDAO2011 ( View Tweet)
#Dementia is ⬇️ing in #RheumatoidArthritis btwn 1980s & now despite theory of NSAIDs being protective for cognitive impairment & they have ⬇️ed over time vs matched pop’n. Maybe due to biological or other factors Olmsted county pop study @RheumNow @eular_org #EULAR2021 OP0216 https://t.co/qTWDtSfPt0
Janet Pope Janetbirdope ( View Tweet)
Yes more lab abnormalities in #Upadactinib vs #Adalimumab in RA RCTs including cytopenias, transaminitis but not creatinine @RheumNow @eular_org #EULAR2021 but no diff in treatmt emergent Adverse events abst OP0128 Yes do labs when on #Upadacitinib https://t.co/5ypKGxuE3U https://t.co/XRjr0gDnIT
Janet Pope Janetbirdope ( View Tweet)
Do you really needs to follow labs for pts on #JAKi ? @eular_org #EULAR2021 OP0128 studied 4.5 years in #upadacitinb 6 RCTs in RA. More grade3 or 4 anemia, low lymph, neutrophils & ⬆️
Janet Pope Janetbirdope ( View Tweet)
Potential rheum board question...
True or False?
MUC5B is a promoter variant that can increase the risk for ILD in RA
Dr. A Palomaki - winner of #EULAR 2021 Abstr award #OP0007 @RheumNow https://t.co/6xKHgXSJ29
k dao KDAO2011 ( View Tweet)
The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden in PsA patients. #EULAR2021 @RheumNow Poster #POS0194 https://t.co/FaIZ7LcoNj
Dr. Rachel Tate uptoTate ( View Tweet)
Prof A Doria introduces SLE-DAS, a new instrument to measure Lupus activity that is continuous and highly sensitive to changes in dz activity #EULAR2021 @rheumnow Watch the oral presentation 6/4/21 Abst#OP0297 https://t.co/gE9QhLL1oj
k dao KDAO2011 ( View Tweet)
What is your treat to target for lupus patients? #EULAR2021 @rheumnow
k dao KDAO2011 ( View Tweet)
ILD in RA is a killer! @eular_org abst OP0099 Admin day from France claims database. ILD was clinically dx in 2.5% & had 3X mortality. Low prevalence compared to some studies of 6% so maybe worst cases but Impt cause of excess death in RA @RheumNow @eular_org @jeffsparks https://t.co/mPfpPSHxsd
Janet Pope Janetbirdope ( View Tweet)
The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden. What drug class do you choose as first line therapy for your PsA patients with prominent enthesitis? #EULAR2021 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Angioni et al characterize PsA clinical remission on a molecular level. c-FOS and CCD50 (YMER) appear to be two key genes. #EULAR2021 poster #POS0409 @RheumNow https://t.co/4lytsgjdzj https://t.co/ySjIXBHTA0
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Does it matter if you diagnose a symptomatic pt w/ nr-axSpA vs r-axSpA? (2/2) Interestingly there are smaller deltas between ASAS40 results in PBO vs nr-axSpA compared to axSpA vs PBO in MEASURE 2, PREVENT, COAST-V, COAST-X, RAPID, C-axSpAnd. Dr. Deodhar #EULAR2021 @RheumNow https://t.co/V8zlZdGltQ
Dr. Rachel Tate uptoTate ( View Tweet)
"50% of time spent in LLDAS = 50% less damage accrual"- Prof E Morand reviews data on low disease activity state in lupus https://t.co/FU3hPvuyRU
k dao KDAO2011 ( View Tweet)
Prof Van Vollenhoven reveals the Definition of Remission in SLE (DORIS 2021): treating SLE to target #EULAR2021 @rheumnow
👉SLEDAI=0
👉MD global<0.5
👉dsDNA, C3/C4 does not matter
👉prednisone <=5 mg/d, stable meds
👉remission can be met at any point (duration not required https://t.co/TwusJkXR19
k dao KDAO2011 ( View Tweet)
Does it matter if you diagnose a symptomatic patient with nr-axSpA vs radiographic axSpA? (1/2)Dr. Deodhar discusses differences in tx withdrawal/dose reduction(PBO) shown in RE-EMBARK, ABILITY-3, C-OPTIMISE. #EULAR2021 @RheumNow https://t.co/wVYsPYFLAi
Dr. Rachel Tate uptoTate ( View Tweet)
MUC5B variant gene in 5634 RA pts had 2X ⬆️ risk of RA ILD - same gene as in IPF. Clinical relevance is unknown but could it result in a novel Rx pathway? ? Effect of sex & smoking @RheumNow @eular_org abst OP0007 #EULAR2021 https://t.co/8XpKjPFfUX
Janet Pope Janetbirdope ( View Tweet)
To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced therapies. Diff from high CV risk pts in Oral Surveillance where Tofacitinib had higher VTE vs TNFi @AbbVie symposium @eular_org #EULAR2021 @RheumNow Hard to reconcile diff risk. https://t.co/AWY2zZPSIb
Janet Pope Janetbirdope ( View Tweet)
Dr. Deodhar reviews ASAS imaging/clinical classification and defines nrAxSpA at #EULAR2021 @RheumNow https://t.co/OdlQvGyNfY
Dr. Rachel Tate uptoTate ( View Tweet)